CPHI (China Pharma Holding) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 11, 2026)


CPHI China Pharma Holding Inc CPHI
26 GF Score
Price $0.57
GF Value $0.24
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is China Pharma Holding Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

China Pharma Holding's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CPHI vs TXMD, RMTI, AYTU: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Pharma Holding Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Margin of Safety % (DCF Earnings Based) falls into.


CPHI
26GF Score
China Pharma Holding Inc CPHI
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Pharma Holding (CPHI) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24. GuruFocus considers China Pharma Holding to be Significantly Overvalued.

Key valuation signals for CPHI:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for CPHI

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price
$0.24
GF Value